[en] [en] INTRODUCTION: The diagnosis of cyst infection in autosomal dominant polycystic kidney disease (ADPKD) is difficult. [18F]FDG PET/CT imaging is helpful, but early diagnosis remains challenging. Procalcitonin (PCT), a serum biomarker for bacterial infections, has not been evaluated in ADPKD-related cyst infections.
METHODS: A retrospective review (between 2009 and 2023) identified all ADPKD patients who were (i) hospitalized (ii) with serum PCT measurements. Cyst infection was conventionally defined. Univariate and multivariate logistic regressions assessed the association between PCT and cyst infection risk.
RESULTS: The cohort included 104 patients (mean age of 65.5 ± 14.9 years; 49% post-kidney transplantation; 16.3% on chronic dialysis). Cyst infections occurred in 24 cases. [18F]FDG PET/CT was performed in 47 patients, detecting cyst infection in 17 cases and non-cystic inflammation in 11. In the whole cohort, CRP levels at admission reached 97.3 [42.8; 164] mg/L. Serum PCT level was measured within 72-h post admission in 83/104 (79%) cases, and the median value reached 0.47 [0.18-2.04] µg/L. A significant correlation was observed between serums levels of PCT and creatinine at admission (r = 0.37, p < 0.05). PCT > 0.59 µg/L significantly predicted cyst infection (OR = 6.30, p = 0.0047). Antibiotics were administered ≥48 h before PCT measurement in 9/24 cases of cyst infection. PCT levels did not significantly differ between patients exposed to antibiotics (0.98 [0.43-2.19] µg/L) or not (1.42 [0.94-3.81] µg/L; p = 0.39). Higher PCT was associated with cyst [18F]FDG uptake above the pathological threshold (OR = 2.01, p = 0.0028).
CONCLUSION: PCT >0.59 µg/L within 72-h post admission is a significant biomarker for cyst infection in ADPKD patients.
Disciplines :
Radiology, nuclear medicine & imaging
Author, co-author :
Abdelmalki, Jihad; Division of Nephrology, ULiège Academic Hospital, Liège, Belgium
Seidel, Laurence ; Université de Liège - ULiège > Département des sciences de la santé publique
Frippiat, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > Infectiologie
Lovinfosse, Pierre ; Université de Liège - ULiège > GIGA > GIGA Platforms - In Vivo Imaging - Nuclear Medicine Division
Jouret, François ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Language :
English
Title :
Procalcitonin levels at hospital admission are increased in cyst infection in patients with autosomal dominant polycystic kidney disease.
Jouret F, Hogan MC, Chebib FT., A practical guide for the management of acute abdominal pain with fever in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transpl Off Publ Eur Dial Transpl Assoc- Eur Ren Assoc. 2022;37(8):1426–1428. doi: 10.1093/ndt/gfab040
Torres VE, Ahn C, Barten TRM, et al. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney Int. 2025;107(2):234–254. doi: 10.1016/j.kint.2024.07.010
Jouret F, Lhommel R, Beguin C, et al. Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6(7):1644–1650. doi: 10.2215/CJN.06900810
Treglia G, Albano D, Rizzo A, et al. Performance of [(18)F]FDG PET/CT in diagnosing cyst infections in patients with autosomal dominant polycystic kidney disease: a systematic review and a bivariate meta-analysis. Diagnostics (Basel). 2024;14(15):1603. doi: 10.3390/diagnostics14151603
Sallée M, Rafat CAA, Zahar J-R, et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4(7):1183–1189. doi: 10.2215/CJN.01870309
Neuville MF, Krzesinski J-M, Jouret F. Serum levels of carbohydrate antigen 19–9 do not systematically increase in case of liver cyst infection in patients with autosomal dominant polycystic kidney disease. Clin Kidney J. 2020;13(3):482–483. doi: 10.1093/ckj/sfz119
Branche A, Neeser O, Mueller B, et al. Procalcitonin to guide antibiotic decision making. Curr Opin Infect Dis. 2019;32(2):130–135. doi: 10.1097/QCO.0000000000000522
Neuville MF, Lovinfosse P, Jadoul A, et al. The use of a visual 4-point scoring scale improves the yield of (18)F-FDG PET-CT imaging in the diagnosis of renal and hepatic cyst infection in patients with autosomal dominant polycystic kidney disease. Eur J Nucl Med Mol Imaging. 2021;48(1):254–259. doi: 10.1007/s00259-020-04903-x
Demuynck S, Lovinfosse P, Seidel L, et al. Standardized 4-point scoring scale of [(18)F]-FDG PET/CT imaging helps in the diagnosis of renal and hepatic cyst infections in patients with autosomal dominant polycystic kidney disease: a validation cohort. Clin Kidney J. 2023;16(12):2542–2548. doi: 10.1093/ckj/sfad159
Dark P, Hossain A, McAuley DF, et al. Biomarker-guided antibiotic duration for hospitalized patients with suspected Sepsis: the ADAPT-Sepsis randomized clinical trial. JAMA. 2024;333(8):682–693. doi: 10.1001/jama.2024.26458
Jouret F, Lhommel R, Devuyst O, et al. Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities. Nephrol Dial Transpl Off Publ Eur Dial Transpl Assoc- Eur Ren Assoc. 2012;27(10):3746–3751. doi: 10.1093/ndt/gfs352
Neuville M, Hustinx R, Jacques J, et al. Diagnostic algorithm in the management of acute febrile abdomen in patients with autosomal dominant polycystic kidney disease. PLOS ONE. 2016;11(8):e0161277. doi: 10.1371/journal.pone.0161277
Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9(1):107. doi: 10.1186/1741-7015-9-107
Iankova I, Thompson-Leduc P, Kirson NY, et al. Efficacy and safety of Procalcitonin guidance in patients with suspected or confirmed Sepsis: a systematic review and meta-analysis. Crit Care Med. 2018;46(5):691–698. doi: 10.1097/CCM.0000000000002928
Smedemark SA, Aabenhus R, Llor C, et al. Biomarkers as point-of-care tests to guide prescription of antibiotics in people with acute respiratory infections in primary care. Cochrane Database Syst Rev. 2022;10(10). doi: 10.1002/14651858.CD010130.pub3
Tao M, Zheng D, Liang X, et al. Diagnostic value of procalcitonin for bacterial infections in patients undergoing hemodialysis: a systematic review and meta-analysis. Ren Fail. 2022;44(1):81–93. doi: 10.1080/0886022X.2021.2021236
Dang J, Scemla A, Loheac C, et al. Efficacy of prolonged antibiotic therapy for renal cyst infections in polycystic kidney disease. Mayo Clin Proc. 2022;97(7):1305–1317. doi: 10.1016/j.mayocp.2022.01.027
Velissaris D, Zareifopoulos N, Lagadinou M, et al. Procalcitonin and sepsis in the emergency department: an update. Eur Rev Med Pharmacol Sci. 2021;25(1):466–479. doi: 10.26355/eurrev_202101_24416
Spellberg B, Ghanem B, Boyles T, et al. ESR and CRP: it is time to stop the zombie tests: author’s response. Clin Microbiol Infect. 2025;31(1):136–137at10.1016/j.cmi.2024.09.029
Lantinga MA, Darding AJM, de Sévaux RGL, et al. International multi-specialty Delphi survey: identification of diagnostic criteria for hepatic and renal cyst infection. Nephron. 2016;134(4):205–214. doi: 10.1159/000446664